Moderna reports encouraging results on its mpox vaccine, as outbreaks in Africa spread
The emergence of a second mpox outbreak in which the virus is spreading from person to person, as well as a sharp increase in overall cases of the disease in several African countries, is straining the world’s capacity to make and distribute vaccine to battle the threat. New options are needed, and a study published Wednesday suggests another may be on the horizon.
The vaccine manufacturer Moderna reported in the journal Cell that a messenger RNA-based mpox vaccine that it is developing was more protective than a vaccine made using the same platform as Bavarian Nordic’s Jynneos vaccine in a study in which non-human primates were vaccinated, then deliberately infected with mpox.
